NIEMANN BRADLEY V. 4
4 · ORTHOFIX INTERNATIONAL N V · Filed Jul 5, 2018
Insider Transaction Report
Form 4
NIEMANN BRADLEY V.
President Biostim
Transactions
- Exercise/Conversion
Common Stock
2018-07-03$21.78/sh+6,250$136,125→ 38,242 total - Exercise/Conversion
Stock Option (right to buy)
2018-07-03−5,000→ 0 totalExercise: $27.37From: 2017-07-01Exp: 2023-07-01→ Common Stock (5,000 underlying) - Award
Common Stock
2018-07-02+2,989→ 26,992 total - Exercise/Conversion
Common Stock
2018-07-03$27.37/sh+5,000$136,850→ 31,992 total - Sale
Common Stock
2018-07-03$56.94/sh−9,100$518,126→ 29,142 total - Sale
Common Stock
2018-07-03$57.35/sh−2,150$123,309→ 26,992 total - Exercise/Conversion
Stock Option (right to buy)
2018-07-03−6,250→ 0 totalExercise: $21.78From: 2017-09-26Exp: 2023-09-26→ Common Stock (6,250 underlying)
Footnotes (4)
- [F1]Represents time-based vesting restricted stock that vests in 25% increments on the first, second, third and fourth anniversaries of the grant date, July 2, 2018.
- [F2]The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b-5-1 trading plan adopted by the reporting person on November 9,2017.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.27 to $57.25, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.27 to $57.45, inclusive. The reporting person undertakes to provide to Orthofix International, N.V., any security holder of Orthofix International N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.